Biochemical studies in Normal Pressure Hydrocephalus (NPH) patients: Change in CSF levels of amyloid precursor protein (APP), amyloid-beta (Aβ) peptide and phospho-tau

Journal of Psychiatric Research

Volumn 45, Issue 4, 2011, Pages 539-547

  Ray, Balmiki ^a   Reyes, Patricio F ^b   Lahiri, Debomoy K ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Health Partners Specialty Center   (United States)

Author keywords

Amyloid beta peptide; Cerebrospinal fluid; Clearance; Disease progression; NPH; Tau

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER; TAU PROTEIN;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID PRESSURE; CHEMICAL ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; LUMBAR PUNCTURE; MALE; NORMOTENSIVE HYDROCEPHALUS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYDROCEPHALUS, NORMAL PRESSURE; MALE; PEPTIDE FRAGMENTS; PHOSPHORYLATION; STATISTICS, NONPARAMETRIC; TAU PROTEINS;

EID: 79952631006     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2010.07.011     Document Type: Article

References (54)

1. Abramoff M.D., Magelhaes P.J., Ram S.J. Image processing with ImageJ. Biophotonics International 2004, 11:36-42.
2. Adams R.D., Fisher C.M., Hakim S., Ojemann R.G., Sweet W.H. Symptomatic occult hydrocephalus with " Normal" cerebrospinal-fluid pressure. A treatable syndrome. New England Journal of Medicine 1965, 273:117-126.
3. Alley G.M., Bailey J.A., Chen D., Ray B., Puli L.K., Tanila H., et al. Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice. Journal of Neuroscience Research 2009, 88:143-154.
4. Andreasen N., Hesse C., Davidsson P., Minthon L., Wallin A., Winblad B., et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Archives of Neurology 1999, 56:673-680.
5. Blennow K., Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurology 2003, 2:605-613.
6. Blennow K., Wallin A., Agren H., Spenger C., Siegfried J., Vanmechelen E. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?. Molecular and Chemical Neuropathology 1995, 26:231-245.
7. Chakravarty A. Unifying concept for Alzheimer's disease, vascular dementia and normal pressure hydrocephalus - a hypothesis. Medical Hypotheses 2004, 63:827-833.
8. Chander H., Chauhan A., Chauhan V. Binding of proteases to fibrillar amyloid-beta protein and its inhibition by Congo red. Journal of Alzheimer's Disease 2007, 12:261-269.
9. Chen Y.F., Wang Y.H., Hsiao J.K., Lai D.M., Liao C.C., Tu Y.K., et al. Normal pressure hydrocephalus: cerebral hemodynamic, metabolism measurement, discharge score, and long-term outcome. Surgical Neurology 2008, 70(Suppl. 1):S69-S77. [discussion S1:77].
10. Citron M., Diehl T.S., Gordon G., Biere A.L., Seubert P., Selkoe D.J. Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:13170-13175.
11. Clarfield A.M. The reversible dementias: do they reverse?. Annals of Internal Medicine 1988, 109:476-486.
12. Colciaghi F., Borroni B., Pastorino L., Marcello E., Zimmermann M., Cattabeni F., et al. [alpha]-Secretase ADAM10 as well as [alpha]APPs is reduced in platelets and CSF of Alzheimer disease patients. Molecular Medicine 2002, 8:67-74.
13. Fagan A.M., Head D., Shah A.R., Marcus D., Mintun M., Morris J.C., et al. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Annals of Neurology 2009, 65:176-183.
14. Fagan A.M., Roe C.M., Xiong C., Mintun M.A., Morris J.C., Holtzman D.M. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Archives of Neurology 2007, 64:343-349.
15. Formichi P., Battisti C., Radi E., Federico A. Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease. Journal of Cellular Physiology 2006, 208:39-46.
16. Fryer J.D., Simmons K., Parsadanian M., Bales K.R., Paul S.M., Sullivan P.M., et al. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. The Journal of Neuroscience 2005, 25:2803-2810.
17. Golomb J., Wisoff J., Miller D.C., Boksay I., Kluger A., Weiner H., et al. Alzheimer's disease comorbidity in normal pressure hydrocephalus: prevalence and shunt response. Journal of Neurology, Neurosurgery, and Psychiatry 2000, 68:778-781.
18. Graff-Radford N.R. Normal pressure hydrocephalus. Neurologic Clinics 2007, 25:809-832. [vii-viii].
19. Grundke-Iqbal I., Iqbal K. Tau pathology generated by overexpression of tau. The American Journal of Pathology 1999, 155:1781-1785.
20. Grundke-Iqbal I., Iqbal K., Tung Y.C., Quinlan M., Wisniewski H.M., Binder L.I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proceedings of the National Academy of Sciences of the United States of America 1986, 83:4913-4917.
21. Hamlat A., Adn M., Sid-ahmed S., Askar B., Pasqualini E. Theoretical considerations on the pathophysiology of normal pressure hydrocephalus (NPH) and NPH-related dementia. Medical Hypotheses 2006, 67:115-123.
22. Hampel H., Teipel S.J., Fuchsberger T., Andreasen N., Wiltfang J., Otto M., et al. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Molecular Psychiatry 2004, 9:705-710.
23. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurology 2006, 5:228-234.
24. Holm A., Savolainen S., Alafuzoff I. Brain biopsy prior to treatment of Alzheimer's disease. Minimally Invasive Neurosurgery 2003, 46:161-164.
25. Iqbal K., Grundke-Iqbal I., Zaidi T., Merz P.A., Wen G.Y., Shaikh S.S., et al. Defective brain microtubule assembly in Alzheimer's disease. Lancet 1986, 2:421-426.
26. Ishikawa M. Clinical guidelines for idiopathic normal pressure hydrocephalus. Neurologia Medico-chirurgica 2004, 44:222-223.
27. Kapaki E.N., Paraskevas G.P., Tzerakis N.G., Sfagos C., Seretis A., Kararizou E., et al. Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease. European Journal of Neurology 2007, 14:168-173.
28. Lahiri D.K., Chen D.M., Lahiri P., Bondy S., Greig N.H. Amyloid, cholinesterase, melatonin, and metals and their roles in aging and neurodegenerative diseases. Annals of the New York Academy of Sciences 2005, 1056:430-449.
29. Lahiri D.K., Farlow M.R., Sambamurti K., Greig N.H., Giacobini E., Schneider L.S. A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Current Drug Targets 2003, 4:97-112.
30. Lee G., Rook S.L. Expression of tau protein in non-neuronal cells: microtubule binding and stabilization. Journal of Cell Science 1992, 102(Pt 2):227-237.
31. Leinonen V., Alafuzoff I., Aalto S., Suotunen T., Savolainen S., Nagren K., et al. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Archives of Neurology 2008, 65:1304-1309.
32. Lewczuk P., Beck G., Esselmann H., Bruckmoser R., Zimmermann R., Fiszer M., et al. Effect of sample collection tubes on cerebrospinal fluid concentrations of tau proteins and amyloid beta peptides. Clinical Chemistry 2006, 52:332-334.
33. Lewczuk P., Kamrowski-Kruck H., Peters O., Heuser I., Jessen F., Popp J., et al. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry 2010, 15:38-45.
34. Lins H., Wichart I., Bancher C., Wallesch C.W., Jellinger K.A., Rosler N. Immunoreactivities of amyloid beta peptide((1-42)) and total tau protein in lumbar cerebrospinal fluid of patients with normal pressure hydrocephalus. Journal of Neural Transmission 2004, 111:273-280.
35. Marksteiner J., Pirchl M., Ullrich C., Oberbauer H., Blasko I., Lederer W., et al. Analysis of cerebrospinal fluid of Alzheimer patients. Biomarkers and toxic properties. Pharmacology 2008, 82:214-220.
36. Peskind E.R., Leverenz J., Farlow M.R., Ito R.K., Provow S.A., Siegel R.S., et al. Clinicopathologic correlations of soluble amyloid beta-protein precursor in cerebrospinal fluid in patients with Alzheimer disease and controls. Alzheimer Disease and Associated Disorders 1997, 11:201-206.
37. Pirttila T., Mehta P.D., Soininen H., Kim K.S., Heinonen O., Paljarvi L., et al. Cerebrospinal fluid concentrations of soluble amyloid beta-protein and apolipoprotein E in patients with Alzheimer's disease: correlations with amyloid load in the brain. Archives of Neurology 1996, 53:189-193.
38. Ray B., Bailey J.A., Sarkar S., Lahiri D.K. Molecular and immunocytochemical characterization of primary neuronal cultures from adult rat brain: differential expression of neuronal and glial protein markers. Journal of Neuroscience Methods 2009, 184:294-302.
39. Ray B., Lahiri D.K. Neuroinflammation in Alzheimer's disease: different molecular targets and potential therapeutic agents including curcumin. Current Opinion in Pharmacology 2009, 9:434-444.
40. Sambamurti K., Greig N.H., Lahiri D.K. Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromolecular Medicine 2002, 1:1-31.
41. Samuels S.C., Silverman J.M., Marin D.B., Peskind E.R., Younki S.G., Greenberg D.A., et al. CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease. Neurology 1999, 52:547-551.
42. Selkoe D.J. Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Annals of the New York Academy of Sciences 2000, 924:17-25.
43. Sengupta A., Kabat J., Novak M., Wu Q., Grundke-Iqbal I., Iqbal K. Phosphorylation of tau at both Thr 231 and Ser 262 is required for maximal inhibition of its binding to microtubules. Archives of Biochemistry and Biophysics 1998, 357:299-309.
44. Sennvik K., Fastbom J., Blomberg M., Wahlund L.O., Winblad B., Benedikz E. Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients. Neuroscience Letters 2000, 278:169-172.
45. Serot J.M., Bene M.C., Foliguet B., Faure G.C. Morphological alterations of the choroid plexus in late-onset Alzheimer's disease. Acta Neuropathologica 2000, 99:105-108.
46. Silverberg G.D. Normal pressure hydrocephalus (NPH): ischaemia, CSF stagnation or both. Brain 2004, 127:947-948.
47. Silverberg G.D., Mayo M., Saul T., Rubenstein E., McGuire D. Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. Lancet Neurology 2003, 2:506-511.
48. Smach M.A., Charfeddine B., Ben Othman L., Lammouchi T., Dridi H., Nafati S., et al. Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease. European Neurology 2009, 62:349-355.
49. Terry R.D. The cytoskeleton in Alzheimer disease. Journal of Neural Transmission: Supplementum 1998, 53:141-145.
50. Van Nostrand W.E., Wagner S.L., Shankle W.R., Farrow J.S., Dick M., Rozemuller J.M., et al. Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:2551-2555.
51. Welge V., Fiege O., Lewczuk P., Mollenhauer B., Esselmann H., Klafki H.W., et al. Combined CSF tau, p-tau181 and amyloid-beta 38/40/42 for diagnosing Alzheimer's disease. Journal of Neural Transmission 2009, 116:203-212.
52. Wind A.W., Schellevis F.G., Van Staveren G., Scholten R.P., Jonker C., Van Eijk J.T. Limitations of the mini-mental state examination in diagnosing dementia in general practice. International Journal of Geriatric Psychiatry 1997, 12:101-108.
53. Wostyn P., Audenaert K., DeDeyn P.P. The Valsalva maneuver and Alzheimer's disease: is there a link?. Current Alzheimer Research 2009, 6:59-68.
54. Xu W., Kawarabayashi T., Matsubara E., Deguchi K., Murakami T., Harigaya Y., et al. Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls. Brain Research 2008, 1219:169-179.